Vir Biotechnology, Inc.’s Post

View organization page for Vir Biotechnology, Inc., graphic

31,856 followers

We are thrilled to announce that the U.S. FDA has cleared our IND application and granted Fast Track designation for our investigational combination therapy, tobevibart and elebsiran, for the treatment of chronic #hepatitis delta infection. Learn more here: https://bit.ly/4eFyNx5 #hepatitisdelta #hepatitisD #hepD

Laura Sepp-Lorenzino, Ph.D.

Chief Scientific Officer at Intellia Therapeutics, Inc.

1mo

So glad to see this moving forward as envisioned as originally designed! ALN-HBV01 and 02!

ANTONIO IZZI

DIRIGENTE MEDICO PRESIDIO OSPEDALIERO D. COTUGNO NAPOLI

2mo

Great success and awesome Tarik Asselah, great friend, that presented breakthrough data at EASL 2024 in Milan 20 days ago...💪💪💯💯✌✌

Like
Reply
Cosmin Oprea

Independent Researcher Hepatitis B / Advocate for awareness of hepatitis B and hepatitis delta

1mo

Congratulations Vir Biotechnology, Inc.. Great news for people living with hepatitis delta.

Roy W.

Business Transformation

2mo

Gilead Sciences, look behind you 😁

Like
Reply
Lisa Richardson

Global Biopharmaceutical Executive | Board Member | Corporate & Business Development | Financial & Capital Markets | Strategic Leadership & Vision Creation | Mentorship

2mo

Congratulations

Gokhul Venkatesh Babu

Senior Associate Scientist at Bayer

2mo

Congratulations

Like
Reply
Carolyn Sutton

Account Development Representative RWE ppd Clinical Research Services Thermo Fisher Scientific

2mo

Congratulations

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics